The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.
May 13th 2024
In case you missed any, below is a recap of every episode of OncLive On Air that aired in April 2024.
Study Endorses Benefits of Population-Based BRCA Screening
September 24th 2020Implementing population-based BRCA1/2 testing is not only cost-effective in high- and upper middle–income countries but could also prevent tens of thousands of breast and ovarian cancer cases compared with the current clinical strategy, which recommends testing only for high-risk women.
First-Line Apatinib/Gefitinib Combo Shows Significant Benefit for EGFR-Mutant NSCLC
September 20th 2020Dual inhibition of both VEGFR and EGFR with the combination of apatinib and gefitinib in the first-line treatment of patients with advanced EGFR-mutant non–small cell lung cancer demonstrated superior progression-free survival.
Giri and Gomella on Fostering a New Framework for Genetic Testing Guidelines in Prostate Cancer
September 14th 2020In our exclusive interview, Dr. Giri and Dr. Gomella discuss the rationale to create the first multidisciplinary, consensus-driven framework for prostate cancer genetic testing, the importance of having a multidisciplinary team weigh in on the recommendations, and key aspects of the guidelines that could have clinical implications for men in this space.
FDA Approves Oncomine Dx Target Test Companion Diagnostic for Pralsetinib in RET+ NSCLC
The FDA has approved the Oncomine Dx Target Test as a companion diagnostic to identify patients with RET fusion–positive non¬–small lung cancer who are candidates to receive the recently approved targeted therapy pralsetinib.
Liquid Biopsy Field Moves Forward But Faces Hurdles
September 2nd 2020Technological advancements are rapidly expanding the potential uses for blood-based liquid biopsies, but broad clinical adoption in cancer care hinges on improving the knowledge base of practicing oncologists and gathering prospective data to validate assays.
Increased Access to Germline Testing Needed in Prostate Cancer
August 27th 2020Germline genetic testing is a key component of prostate cancer treatment, and broader testing criteria combined with reduced barriers to these tests could result in better informed care, including preventive surveillance, according to data from a recent study.
FDA Grants Priority Review to Tepotinib for METex14-Altered Metastatic NSCLC
The FDA has granted a priority review designation to new drug application for tepotinib as a treatment for patient with metastatic non–small cell lung cancer whose tumors harbor a MET exon 14 skipping mutation identified via an FDA-approved test.
Companion Diagnostic, Targeted Therapy Approvals Rise in Tandem
August 23rd 2020As precision medicine evolves in oncology, companion diagnostics are broadly and increasingly being adopted to guide treatment decisions, enabling clinicians to better and more precisely direct patients to therapies that best suit their unique genomic profiles.
Presence of ctDNA, CTCs Independently Linked With Early-Stage TNBC Recurrence
August 19th 2020A new, recently patented liquid biopsy device designed to detect small amounts of genetic and cellular material from tumors in the bloodstream of patients with early-stage, recurrent triple negative breast cancer, following neoadjuvant chemotherapy, has shown great accuracy and sensitivity.
Dabrafenib Plus Trametinib Elicits Encouraging Responses in BRAF V600E-Mutant Tumors
The combination of dabrafenib and trametinib elicited favorable response rates in a mixed histology cohort of pretreated patients with solid tumors, lymphomas, and multiple myeloma whose tumors harbored a BRAF V600 mutation.
Entrectinib Approved in Europe for NTRK+ Tumors and ROS1+ NSCLC
August 3rd 2020The European Commission has approved entrectinib for the treatment of adult and pediatric patients ≥12 years of age with solid tumors that harbor an NTRK fusion, as well as for the treatment of adult patients with ROS1-positive, advanced non—small cell lung cancer not previously treated with ROS1 inhibitors.
Long-Term Consequences for Cancer Detection Loom Amid COVID-19
July 30th 2020The coronavirus disease 2019 has disrupted the global delivery of coordinated cancer care, resulting in declines in routine screening and referrals that could lead to thousands of excess deaths due to delayed diagnoses, experts warn.